Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Modafinil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | EDNRB | P24530 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | MC3R | P41968 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Modafinil SCHEMBL3238686 | 0.96 | CYP2D6 (0.44) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| Armodafinil SCHEMBL34489 | 0.96 | CYP2D6 (0.44) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| Modafinil SCHEMBL1560974 | 0.96 | CYP2D6 (0.44) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| (S)-Modafinil SCHEMBL1403524 | 0.96 | CYP2D6 (0.44) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| Modafinil SCHEMBL34488 | 0.96 | CYP2D6 (0.44) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| Modafinil SCHEMBL3914634 | 0.95 | PKM (0.41) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| Modafinil SCHEMBL3921259 | 0.95 | PKM (0.41) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| Modafinil SCHEMBL19025521 | 0.95 | PKM (0.41) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| Modafinil SCHEMBL193837 | 0.92 | CYP2D6 (0.41) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 | |
| Modafinil SCHEMBL193927 | 0.91 | ALDH1A1 (0.40) | EPHX1CYP1A2CYP2D6PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101972240-A | Modafinil Composition | CEPHALON INC | 2011-02-16 | — | — | CN | claimed |
| US-7566805-B2 | Modafinil compositions | CEPHALON, INC. (US) | 2009-07-28 | — | — | US | claimed |
| EP-1670753-A4 | MODAFINIL COMPOSITIONS | CEPHALON INC (US) | 2008-01-02 | — | — | EP | claimed |
| US-20070021510-A1 | Modafinil compositions | CEPHALON, INC. (US) | 2007-01-25 | — | — | US | claimed |
| EP-1670753-A2 | MODAFINIL COMPOSITIONS | CEPHALON, INC. (US) | 2006-06-21 | — | — | EP | claimed |
| WO-2005023198-A2 | MODAFINIL COMPOSITIONS | CEPHALON, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| CN-101972240-B | Modafinil composition | CEPHALON INC | 2012-07-25 | — | — | CN | disclosed |
| CN-101972240-A | Modafinil Composition | CEPHALON INC | 2011-02-16 | — | — | CN | disclosed |
| US-7566805-B2 | Modafinil compositions | CEPHALON, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| EP-1670753-A4 | MODAFINIL COMPOSITIONS | CEPHALON INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070021510-A1 | Modafinil compositions | CEPHALON, INC. (US) | 2007-01-25 | — | — | US | disclosed |
| EP-1670753-A2 | MODAFINIL COMPOSITIONS | CEPHALON, INC. (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005023198-A2 | MODAFINIL COMPOSITIONS | CEPHALON, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021510-A1 | Modafinil compositions | CYP3A4, COMT, CYP3A43 | SLC6A3 58/4885EPHX1 3927/4885CYP1A2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.